Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial

Nan, Chuanchuan1,2,4; Zhang, Xiaowu3; Huang, Wei2; Zhu, Biao5; Zhao, Jianghong6; Lu, Song7; Xian, Lewu8; Liu, Kaizhong9; Ma, Gang10; Yang, Wei1; Huang, Mingguang11; Zhou, Dongmin12; Zhang, Ming13; Duan, Yan11; Wu, Guixin14; Jiang, Zhengying14; Zhang, Li15; He, Xinrong10; Chen, Yuhong16; Xing, Xuezhong17; Wang, Changsong1,2; Wang, Donghao3; Yu, Kaijiang1

2023-12-01

10.1016/j.phrs.2023.106991

PHARMACOLOGICAL RESEARCH   影响因子和分区

1043-6618

1096-1186

Carrimycin is a potential immune-regulating agent for sepsis in patients with tumors. In this study, we inves-tigated its effects on inflammation and immune function in tumor patients with sepsis. In total, 120 participants were randomized to receive either carrimycin treatment (400 mg/day) (n = 62) or placebo (n = 58) for 7 days. The primary outcomes were immune-related indicators. Subsequently, patients were stratified into two sub-groups (CD4 < 38.25% and CD8 < 25.195%). Ninety-nine participants were analyzed: 47 and 52 in the carrimycin and placebo groups, respectively. HLA-DR levels were rapidly increased in the carrimycin group; however, the placebo group initially experienced a decline in HLA-DR level at 1 day after administration. In the subgroup with CD4 < 38.25%, the carrimycin group exhibited significantly higher HLA-DR levels than the placebo group (2.270, P = 0.023) 1 day after administration and the degree of increase in HLA-DR in the carrimycin group was higher than that in the placebo group (2.057, P = 0.040). In the CD8 < 25.195% subgroup, the carrimycin group demonstrated significantly higher levels of CD8+ T cells than the placebo group at 3 (2.300, P = 0.027) and 5 (2.106, P = 0.035) days after administration. Carrimycin intervention led to significant reductions in the SOFA, APACHE II, PCT, and CRP levels. No adverse events were observed. In tumor patients with sepsis, particularly in those experiencing immunological suppression, carrimycin effectively regulates immune responses by increasing HLA-DR and CD8(+) T cell levels and plays an anti-infective role, reducing disease severity.

Carrimycin CD8+T cells HLA-DR Immune Sepsis Tumor

SCI

英语

其他

Pharmacology & Pharmacy

Pharmacology & Pharmacy

WOS:001124812700001

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

PHARMACOLOGY & TOXICOLOGY

Web of Science

1.Harbin Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Harbin 150001, Peoples R China
2.Harbin Med Univ, Canc Hosp, Dept Crit Care Med, Harbin 150001, Peoples R China
3.Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin 300060, Peoples R China
4.Jinan Univ, Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Affiliated Hosp 1,Clin Med Coll 2,Dept Crit Care, Shenzhen 518000, Peoples R China
5.Fudan Univ, Dept Crit Care Med, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
6.Hunan Canc Hosp, Dept Crit Care Med, Changsha 410013, Hunan, Peoples R China
7.Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Crit Care Med, Chengdu 610041, Peoples R China
8.Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Crit Care Med, Guangzhou 510000, Peoples R China
9.Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc, Dept Crit Care Med, Hangzhou 310022, Peoples R China
10.Sun Yat Sen Univ, Canc Ctr, Dept Crit Care Med, Guangzhou 510000, Peoples R China
11.Shanxi Med Univ, Chinese Acad Med Sci, Shanxi Prov Canc Hosp, Shanxi Hosp,Canc Hosp Affiliated,Dept Crit Care M, Taiyuan 030000, Peoples R China
12.Zhengzhou Univ, Affiliated Canc Hosp, Dept Crit Care Med, Zhengzhou 450000, Peoples R China
13.Zhejiang Univ, Affiliated Hangzhou Canc Hosp, Dept Crit Care Med, Sch Med, Hangzhou 310002, Peoples R China
14.Chongqing Univ, Canc Hosp, Dept Crit Care Med, Chongqing 404100, Peoples R China
15.Hubei Canc Hosp, Dept Crit Care Med, Wuhan 430079, Hubei, Peoples R China
16.Fourth Hosp Hebei Med Univ, Dept Crit Care Med, Shijiazhuang 050000, Peoples R China
17.Chinese Acad Med Sci, Canc Hosp, Dept Crit Care Med, Beijing 100000, Peoples R China

Nan, Chuanchuan,Zhang, Xiaowu,Huang, Wei,et al. Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial[J]. PHARMACOLOGICAL RESEARCH,2023,198.

Nan, Chuanchuan.,Zhang, Xiaowu.,Huang, Wei.,Zhu, Biao.,Zhao, Jianghong.,...&Yu, Kaijiang.(2023).Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial.PHARMACOLOGICAL RESEARCH,198.

Nan, Chuanchuan,et al."Effects of carrimycin on biomarkers of inflammation and immune function in tumor patients with sepsis: A multicenter double-blind randomized controlled trial".PHARMACOLOGICAL RESEARCH 198(2023).